



Targeted therapies in *EGFRm* NSCLC: an Asian perspective

Saturday 20 November 2021

12:00–13:30 (SGT)

Channel 2

AstraZeneca would like to invite you to their symposium discussing Asian perspectives on utilising targeted therapies to treat patients with *EGFRm* NSCLC in the adjuvant and advanced settings. Pre-recorded presentations will be complemented by a live Q&A session moderated by a faculty of experts.

We hope you can join us for what promises to be an engaging and educational meeting.

Faculty

Yi-Long Wu

Guangzhou, China
(Chair)

Masahiro Tsuboi

Chiba, Japan

Myung-Ju Ahn

Seoul, South Korea

James Yang

Taipei City, Taiwan

Agenda

Welcome and introductions

Yi-Long Wu, Chair

Improving outcomes through personalised adjuvant therapy in patients with resectable *EGFRm* NSCLC

Masahiro Tsuboi

Optimising treatment and patient identification in resectable *EGFRm* NSCLC

Myung-Ju Ahn and Masahiro Tsuboi; moderated by Yi-Long Wu

Redefining treatment practices post-progression with first-line third-generation EGFR-TKIs in patients with metastatic *EGFRm* NSCLC

Myung-Ju Ahn

EGFRm NSCLC in Asia: enhancing current treatment practices in patients with metastatic disease

Myung-Ju Ahn and James Yang; moderated by Yi-Long Wu

Meeting close

Yi-Long Wu
